Nangibotide

Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8) . Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure[1][2][3][4][5].

Product Specifications

CAS Number

[2014384-91-7]

Product Name Alternative

LR12

UNSPSC

12352209

Target

Apoptosis; Interleukin Related; NF-κB; NOD-like Receptor (NLR) ; TREM receptor

Type

Peptides

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/nangibotide.html

Purity

98.52

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@@H](C(NCC(N[C@@H](CS)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)NC([C@H](CCC(O)=O)NC(CNC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C54H82N14O22S2

Molecular Weight

1343.44

References & Citations

[1]Cuvier V, et, al. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol. 2018 Oct;84 (10) :2270-2279.|[2]Zhong Y, et al. Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone. Inflammopharmacology. 2022 Jun;30 (3) :1107-1117.|[3]Wang Y, et al. LR12 Promotes Liver Repair by Improving the Resolution of Inflammation and Liver Regeneration in Mice with Thioacetamide- (TAA-) Induced Acute Liver Failure. Mediators Inflamm. 2021 May 28;2021:2327721.|[4]Dubar M, et al. Effects of Porphyromonas gingivalis LPS and LR12 peptide on TREM-1 expression by monocytes. J Clin Periodontol. 2018 Jul;45 (7) :799-805.|[5]Liu T, et al. Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation. Sci Rep. 2016 Dec 22;6:39473.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

Phase 2

Citation 01

Int Immunopharmacol. 2024 Sep 30;143 (Pt 1) :113274.|J Headache Pain. 2024 Jan 5;25 (1) :3.|Cell Signal. 2024 Dec:124:111458.|Stanford University. 2025.